Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | KIF5B | P33176 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 11/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.35 |
| ▸ | WHR1 | P49842 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469177 | 0.98 | RET (0.38) | RETKIF5BCYP3A4CYP2D6KCNH2 | |
| SCHEMBL6469454 | 0.93 | FGFR4 (0.38) | RETKIF5BWHR1EHMT2HRH3 | |
| SCHEMBL6469079 | 0.91 | MCHR1 (0.36) | RETKIF5BCYP3A4CYP2D6KCNH2 | |
| Trifluoroacetic Acid SCHEMBL6470948 | 0.89 | RET (0.42) | RETKIF5BCYP3A4CYP2D6KCNH2 | |
| SCHEMBL6469154 | 0.87 | KDR (0.40) | RETEHMT2HRH3 | |
| Trifluoroacetic Acid SCHEMBL6469172 | 0.87 | RET (0.40) | RETKIF5BCYP3A4CYP2D6KCNH2 | |
| SCHEMBL6469215 | 0.87 | KDR (0.41) | RETEHMT2 | |
| SCHEMBL6469285 | 0.86 | HRH3 (0.36) | RETKIF5BWHR1EHMT2HRH3 | |
| SCHEMBL6470132 | 0.86 | PDK1 (0.39) | RETMCHR1AURKA | |
| SCHEMBL6467496 | 0.85 | AVPR1B (0.41) | RETAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | claimed |
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | REPLIDYNE, INC. | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124562-A1 | Bis-quinazoline compounds for the treatment of bacterial infections | POLI, POLK, POLB | RET 4244/4885KIF5B 2609/4885CYP3A4 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.